[Form 4] Centessa Pharmaceuticals plc American Insider Trading Activity
Centessa Pharmaceuticals plc (CNTA) reporting person Hussain Iqbal J, General Counsel, executed option exercise and a sale on 08/15/2025. The filing shows the reporting person exercised a share option to acquire 6,000 ordinary shares at an exercise price of $5.84 per share and immediately sold 6,000 ordinary shares at $17.23 per share, leaving 105,386 shares owned directly after the transactions. The Form 4 notes 5,500 ordinary shares are held indirectly by the reporting person鈥檚 spouse. The reported sale was effected under a Rule 10b5-1 trading plan adopted on September 14, 2024.
Centessa Pharmaceuticals plc (CNTA), persona che presenta la comunicazione Hussain Iqbal J, General Counsel, ha esercitato opzioni e effettuato una vendita il 15/08/2025. La registrazione indica che la persona ha esercitato un'opzione per acquisire 6.000 azioni ordinarie al prezzo di esercizio di $5,84 per azione e ha immediatamente venduto 6.000 azioni ordinarie a $17,23 per azione, lasciando 105.386 azioni di propriet脿 diretta dopo le operazioni. Il Modulo 4 segnala che 5.500 azioni ordinarie sono detenute indirettamente dal coniuge della persona che presenta la comunicazione. La vendita riportata 猫 stata eseguita nell'ambito di un piano di trading Rule 10b5-1 adottato il 14 settembre 2024.
Centessa Pharmaceuticals plc (CNTA), persona informante Hussain Iqbal J, Asesor General, realiz贸 el ejercicio de una opci贸n y una venta el 15/08/2025. El informe muestra que la persona ejerci贸 una opci贸n para adquirir 6.000 acciones ordinarias a un precio de ejercicio de $5.84 por acci贸n y vendi贸 inmediatamente 6.000 acciones ordinarias a $17.23 por acci贸n, quedando con 105.386 acciones en propiedad directa tras las transacciones. El Formulario 4 indica que 5.500 acciones ordinarias se mantienen de forma indirecta por el c贸nyuge de la persona informante. La venta reportada se efectu贸 bajo un plan de negociaci贸n Rule 10b5-1 adoptado el 14 de septiembre de 2024.
Centessa Pharmaceuticals plc (CNTA) 氤搓碃鞚� Hussain Iqbal J, 氩曤齑濌磩鞚� 2025-08-15鞐� 鞓奠厴 頄夓偓 氚� 毵る弰毳� 鞁ろ枆頄堨姷雼堧嫟. 鞝滌稖靹滊鞐� 霐半ゴ氅� 氤搓碃鞚胳潃 欤茧嫻 頄夓偓臧� $5.84鞐� 氤错喌欤� 6,000欤茧ゼ 旆摑頃橂姅 鞓奠厴鞚� 頄夓偓頃橃榾瓿�, 歃夓嫓 氤错喌欤� 6,000欤茧ゼ 欤茧嫻 $17.23鞐� 毵る弰頃橃棳 瓯半灅 頉� 歆侅爲 氤挫湢 欤检嫕鞚� 105,386欤� 雮晿鞀惦媹雼�. Form 4鞐愲姅 氤搓碃鞚胳潣 氚办毎鞛愱皜 臧勳爲鞝侅溂搿� 氤挫湢頃� 氤错喌欤� 5,500欤缄皜 旮办灛霅橃柎 鞛堨姷雼堧嫟. 鞁犼碃霅� 毵る弰電� 2024雲� 9鞗� 14鞚� 毂勴儩霅� Rule 10b5-1 瓯半灅瓿勴殟鞐� 霐半澕 鞚措（鞏挫鞀惦媹雼�.
Centessa Pharmaceuticals plc (CNTA), personne d茅clarante Hussain Iqbal J, General Counsel, a effectu茅 l'exercice d'options et une vente le 15/08/2025. Le d茅p么t indique que la personne a exerc茅 une option pour acqu茅rir 6 000 actions ordinaires au prix d'exercice de 5,84 $ par action et a imm茅diatement vendu 6 000 actions ordinaires 脿 17,23 $ par action, laissant 105 386 actions d茅tenues directement apr猫s les op茅rations. Le formulaire 4 pr茅cise que 5 500 actions ordinaires sont d茅tenues indirectement par l'茅poux/茅pouse de la personne d茅clarante. La vente rapport茅e a 茅t茅 r茅alis茅e dans le cadre d'un plan de n茅gociation Rule 10b5-1 adopt茅 le 14 septembre 2024.
Centessa Pharmaceuticals plc (CNTA), meldepflichtige Person Hussain Iqbal J, General Counsel, hat am 15.08.2025 Optionsaus眉bung und einen Verkauf vorgenommen. Die Meldung zeigt, dass die Person eine Aktienoption zum Erwerb von 6.000 Stammaktien zum Aus眉bungspreis von $5,84 je Aktie ausge眉bt und unmittelbar 6.000 Stammaktien zu $17,23 je Aktie verkauft hat, sodass nach den Transaktionen 105.386 Aktien direkt gehalten werden. Im Formular 4 wird vermerkt, dass 5.500 Stammaktien indirekt vom Ehepartner der meldenden Person gehalten werden. Der gemeldete Verkauf erfolgte im Rahmen eines Rule-10b5-1-Handelsplans, der am 14. September 2024 angenommen wurde.
- Transparent disclosure of exercise and sale details including prices, amounts, and 10b5-1 plan adoption date
- AG真人官方ized spread between exercise price ($5.84) and sale price ($17.23) for the exercised options
- Direct holdings decreased from 111,386 to 105,386 ordinary shares following the sale
- Insider sold shares (6,000) which may be viewed negatively by some investors despite 10b5-1 plan usage
Insights
TL;DR: Officer exercised options and sold the same number of shares under a pre-existing 10b5-1 plan; net direct holdings modestly reduced.
The transaction is a routine insider exercise of vested options followed by an immediate sale of the acquired shares. The exercise price of $5.84 compared with the sale price of $17.23 indicates the reporting person realized a spread on the exercised options. The filing discloses 111,386 shares before the sale, 105,386 after, and 5,500 indirectly held by a spouse, providing transparent disclosure of insider ownership. This appears procedural and consistent with planned disposition rather than opportunistic timing because the sale was made pursuant to a 10b5-1 plan adopted 09/14/2024.
TL;DR: Disclosure aligns with Section 16 requirements and 10b5-1 safe-harbor usage; no governance red flags in the filing itself.
The Form 4 properly identifies the reporting person鈥檚 role (General Counsel and Officer), details the option exercise (6,000 shares exercisable 02/19/2022 through 02/19/2031) and the contemporaneous sale executed under a documented 10b5-1 trading plan. Signatures and explanation footnotes are present. From a governance perspective, the filing meets standard disclosure norms; the presence of a written trading plan reduces concerns about opportunistic insider trading, though the filing does show a reduction in direct holdings.
Centessa Pharmaceuticals plc (CNTA), persona che presenta la comunicazione Hussain Iqbal J, General Counsel, ha esercitato opzioni e effettuato una vendita il 15/08/2025. La registrazione indica che la persona ha esercitato un'opzione per acquisire 6.000 azioni ordinarie al prezzo di esercizio di $5,84 per azione e ha immediatamente venduto 6.000 azioni ordinarie a $17,23 per azione, lasciando 105.386 azioni di propriet脿 diretta dopo le operazioni. Il Modulo 4 segnala che 5.500 azioni ordinarie sono detenute indirettamente dal coniuge della persona che presenta la comunicazione. La vendita riportata 猫 stata eseguita nell'ambito di un piano di trading Rule 10b5-1 adottato il 14 settembre 2024.
Centessa Pharmaceuticals plc (CNTA), persona informante Hussain Iqbal J, Asesor General, realiz贸 el ejercicio de una opci贸n y una venta el 15/08/2025. El informe muestra que la persona ejerci贸 una opci贸n para adquirir 6.000 acciones ordinarias a un precio de ejercicio de $5.84 por acci贸n y vendi贸 inmediatamente 6.000 acciones ordinarias a $17.23 por acci贸n, quedando con 105.386 acciones en propiedad directa tras las transacciones. El Formulario 4 indica que 5.500 acciones ordinarias se mantienen de forma indirecta por el c贸nyuge de la persona informante. La venta reportada se efectu贸 bajo un plan de negociaci贸n Rule 10b5-1 adoptado el 14 de septiembre de 2024.
Centessa Pharmaceuticals plc (CNTA) 氤搓碃鞚� Hussain Iqbal J, 氩曤齑濌磩鞚� 2025-08-15鞐� 鞓奠厴 頄夓偓 氚� 毵る弰毳� 鞁ろ枆頄堨姷雼堧嫟. 鞝滌稖靹滊鞐� 霐半ゴ氅� 氤搓碃鞚胳潃 欤茧嫻 頄夓偓臧� $5.84鞐� 氤错喌欤� 6,000欤茧ゼ 旆摑頃橂姅 鞓奠厴鞚� 頄夓偓頃橃榾瓿�, 歃夓嫓 氤错喌欤� 6,000欤茧ゼ 欤茧嫻 $17.23鞐� 毵る弰頃橃棳 瓯半灅 頉� 歆侅爲 氤挫湢 欤检嫕鞚� 105,386欤� 雮晿鞀惦媹雼�. Form 4鞐愲姅 氤搓碃鞚胳潣 氚办毎鞛愱皜 臧勳爲鞝侅溂搿� 氤挫湢頃� 氤错喌欤� 5,500欤缄皜 旮办灛霅橃柎 鞛堨姷雼堧嫟. 鞁犼碃霅� 毵る弰電� 2024雲� 9鞗� 14鞚� 毂勴儩霅� Rule 10b5-1 瓯半灅瓿勴殟鞐� 霐半澕 鞚措（鞏挫鞀惦媹雼�.
Centessa Pharmaceuticals plc (CNTA), personne d茅clarante Hussain Iqbal J, General Counsel, a effectu茅 l'exercice d'options et une vente le 15/08/2025. Le d茅p么t indique que la personne a exerc茅 une option pour acqu茅rir 6 000 actions ordinaires au prix d'exercice de 5,84 $ par action et a imm茅diatement vendu 6 000 actions ordinaires 脿 17,23 $ par action, laissant 105 386 actions d茅tenues directement apr猫s les op茅rations. Le formulaire 4 pr茅cise que 5 500 actions ordinaires sont d茅tenues indirectement par l'茅poux/茅pouse de la personne d茅clarante. La vente rapport茅e a 茅t茅 r茅alis茅e dans le cadre d'un plan de n茅gociation Rule 10b5-1 adopt茅 le 14 septembre 2024.
Centessa Pharmaceuticals plc (CNTA), meldepflichtige Person Hussain Iqbal J, General Counsel, hat am 15.08.2025 Optionsaus眉bung und einen Verkauf vorgenommen. Die Meldung zeigt, dass die Person eine Aktienoption zum Erwerb von 6.000 Stammaktien zum Aus眉bungspreis von $5,84 je Aktie ausge眉bt und unmittelbar 6.000 Stammaktien zu $17,23 je Aktie verkauft hat, sodass nach den Transaktionen 105.386 Aktien direkt gehalten werden. Im Formular 4 wird vermerkt, dass 5.500 Stammaktien indirekt vom Ehepartner der meldenden Person gehalten werden. Der gemeldete Verkauf erfolgte im Rahmen eines Rule-10b5-1-Handelsplans, der am 14. September 2024 angenommen wurde.
FAQ
What did CNTA insider Hussain Iqbal J report on the Form 4?
Was the sale executed under a 10b5-1 trading plan for CNTA?
How many CNTA shares does the reporting person own after the transaction?
What were the exercise and sale prices reported?
Does the filing indicate vesting terms for the option?
